Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Related Citations for PubMed (Select 21804401)

1.
3.

Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.

McKenney JM.

Postgrad Med. 2012 Jan;124(1):7-20. doi: 10.3810/pgm.2012.01.2513. Review.

PMID:
22314110
4.

Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.

Brinton EA, Kashyap ML, Vo AN, Thakkar RB, Jiang P, Padley RJ.

Am J Cardiovasc Drugs. 2011 Jun 1;11(3):179-87. doi: 10.2165/11592560-000000000-00000.

PMID:
21619381
5.

Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.

Kim SH, Kim MK, Lee HY, Kang HJ, Kim YJ, Park BJ, Kim HS.

Clin Ther. 2011 Oct;33(10):1357-64. doi: 10.1016/j.clinthera.2011.08.015. Epub 2011 Sep 28.

PMID:
21955937
6.

Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.

Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ.

Am J Cardiovasc Drugs. 2009;9(2):69-79. doi: 10.2165/00129784-200909020-00001.

PMID:
19331435
7.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
8.

Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.

Cefali EA, Simmons PD, Stanek EJ, McGovern ME, Kissling CJ.

Int J Clin Pharmacol Ther. 2007 Feb;45(2):78-88.

PMID:
17323787
9.

Effects of niacin on glucose control in patients with dyslipidemia.

Goldberg RB, Jacobson TA.

Mayo Clin Proc. 2008 Apr;83(4):470-8. doi: 10.4065/83.4.470. Review.

PMID:
18380993
10.

Niacin: an old drug rejuvenated.

Kamanna VS, Ganji SH, Kashyap ML.

Curr Atheroscler Rep. 2009 Jan;11(1):45-51. Review.

PMID:
19080727
11.

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.

Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH.

Am J Cardiovasc Drugs. 2008;8(2):69-81.

PMID:
18422390
12.

Niacin: the evidence, clinical use, and future directions.

Villines TC, Kim AS, Gore RS, Taylor AJ.

Curr Atheroscler Rep. 2012 Feb;14(1):49-59. doi: 10.1007/s11883-011-0212-1. Review.

PMID:
22037771
13.

Niacin use and cutaneous flushing: mechanisms and strategies for prevention.

Davidson MH.

Am J Cardiol. 2008 Apr 17;101(8A):14B-19B. doi: 10.1016/j.amjcard.2008.02.028. Review.

PMID:
18375236
14.

Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.

Vosper H.

Br J Pharmacol. 2009 Sep;158(2):429-41. doi: 10.1111/j.1476-5381.2009.00349.x. Epub 2009 Jul 20. Review.

15.

The role of niacin in lipid-lowering treatment: are we aiming too high?

Gouni-Berthold I, Berthold HK.

Curr Pharm Des. 2013;19(17):3094-106. Review.

PMID:
23317400
16.

Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.

Kamal-Bahl S, Watson DJ, Ambegaonkar BM.

Clin Ther. 2009 Jan;31(1):130-40. doi: 10.1016/j.clinthera.2009.01.011.

PMID:
19243714
17.

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Chrysant SG, Ibrahim M.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. Review.

PMID:
16849903
18.

A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.

Yiu KH, Cheung BM, Tse HF.

Expert Opin Investig Drugs. 2010 Mar;19(3):437-49. doi: 10.1517/13543781003623223. Review.

PMID:
20141348
19.

Mechanisms of flushing due to niacin and abolition of these effects.

Sood A, Arora R.

J Clin Hypertens (Greenwich). 2009 Nov;11(11):685-9. doi: 10.1111/j.1559-4572.2008.00050.x. Review.

PMID:
19878384
20.

Optimal pharmacotherapy to combat the atherogenic lipid triad.

Chapman MJ, Redfern JS, McGovern ME, Giral P.

Curr Opin Cardiol. 2011 Sep;26(5):403-11. doi: 10.1097/HCO.0b013e32834965e9. Review.

PMID:
21730827
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk